Identification of the first inhibitor of the GBP1:PIM1 interaction. Implications for the development of a new class of anticancer agents against paclitaxel resistant cancer cells

Journal of Medicinal Chemistry

Volumn 57, Issue 19, 2014, Pages 7916-7932

  Andreoli, Mirko ^a   Persico, Marco ^b   Kumar, Ajay ^d   Orteca, Nausicaa ^b   Kumar, Vineet ^c   Pepe, Antonella ^c   Mahalingam, Sakkarapalayam ^h   Alegria, Antonio E ^e   Petrella, Lella ^f   Sevciunaite, Laima ^f   Camperchioli, Alessia ^f   Mariani, Marisa ^a   Di Dato, Antonio ^b   Novellino, Ettore ^b   Scambia, Giovanni ^g   Malhotra, Sanjay V ^c   Ferlini, Cristiano ^a   Fattorusso, Caterina ^b  

^a DANBURY HOSPITAL   (United States)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^d Technology and Environment   (United States)

^e UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^f CATHOLIC UNIVERSITY   (Italy)

^g CATHOLIC UNIVERSITY   (Italy)

^h PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AZAPODOPHYLLOTOXIN; ANTINEOPLASTIC AGENT; ETOPOSIDE; PACLITAXEL; PODOPHYLLOTOXIN; PROTEIN INHIBITOR; RECOMBINANT PROTEIN; TUBULIN; UNCLASSIFIED DRUG; GBP1 PROTEIN, HUMAN; GUANINE NUCLEOTIDE BINDING PROTEIN; PIM1 PROTEIN, HUMAN; PROTEIN KINASE PIM 1;

ARTICLE; BINDING SITE; BIOINFORMATICS; CANCER CELL; CONFORMATION; CYTOSKELETON; DRUG POTENCY; DRUG RESISTANCE; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VIVO STUDY; MICROTUBULE; MOLECULAR MODEL; MUTAGENESIS; OVARY CANCER; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; SURFACE PLASMON RESONANCE; ANTAGONISTS AND INHIBITORS; BIOLOGY; CHEMICAL STRUCTURE; CHEMISTRY; DRUG DEVELOPMENT; MOLECULAR DOCKING; SYNTHESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; BINDING SITES; CELL LINE, TUMOR; COMPUTATIONAL BIOLOGY; DRUG DISCOVERY; DRUG RESISTANCE, NEOPLASM; GTP-BINDING PROTEINS; HUMANS; MODELS, MOLECULAR; MOLECULAR DOCKING SIMULATION; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-PIM-1;

EID: 84907921127     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5009902     Document Type: Article

References (42)

1. Sullivan, K. F.; Cleveland, D. W. Identification of conserved isotype-defining variable region sequences for four vertebrate beta tubulin polypeptide classes Proc. Natl. Acad. Sci. U. S. A. 1986, 83, 4327-4331
2. Raspaglio, G.; Filippetti, F.; Prislei, S.; Penci, R.; De Maria, I.; Cicchillitti, L.; Mozzetti, S.; Scambia, G.; Ferlini, C. Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3 flanking region Gene 2008, 409, 100-108
3. Ferlini, C.; Raspaglio, G.; Cicchillitti, L.; Mozzetti, S.; Prislei, S.; Bartollino, S.; Scambia, G. Looking at drug resistance mechanisms for microtubule interacting drugs: does TUBB3 work? Curr. Cancer Drug Targets 2007, 7, 704-712
4. Seve, P.; Dumontet, C. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol. 2008, 9, 168-175
5. Mariani, M.; Shahabi, S.; Sieber, S.; Scambia, G.; Ferlini, C. Class III beta-tubulin (TUBB3): more than a biomarker in solid tumors? Curr. Mol. Med. 2011, 11, 726-731
6. De Donato, M.; Mariani, M.; Petrella, L.; Martinelli, E.; Zannoni, G. F.; Vellone, V.; Ferrandina, G.; Shahabi, S.; Scambia, G.; Ferlini, C. Class III beta-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer J. Cell. Physiol. 2012, 227, 1034-1041
7. Katsetos, C. D.; Draber, P. Tubulins as therapeutic targets in cancer: from bench to bedside Curr. Pharm. Des. 2012, 18, 2778-2792
8. Arkin, M. R.; Wells, J. A. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream Nature Rev. Drug Discovery 2004, 3, 301-317
9. Bonacci, T. M.; Mathews, J. L.; Yuan, C.; Lehmann, D. M.; Malik, S.; Wu, D. Differential targeting of Gbetagamma-subunit signaling with small molecules Science 2006, 312, 443-446
10. Gestwicki, J. E.; Crabtree, G. R.; Graef, I. A. Harnessing chaperones to generate small-molecule inhibitors of amyloid beta aggregation Science 2004, 306, 865-869
11. Canel, C.; Moraes, R. M.; Dayan, F. E.; Ferreira, D. Molecules of interest: podophyllotoxin Phytochemistry 2000, 54, 115-120
12. Hartwell, J. L.; Schrecker, A. W. Components of podophyllin. V. The constitution of podophyllotoxin J. Am. Chem. Soc. 1951, 73, 2909-2916
13. Bohlin, L.; Rosen, B. Podophyllotoxin derivatives: drug discovery and development Drug Discovery Today 1996, 1, 343-351
14. Kumar, A.; Alegria, A. E. Synthesis of novel functionalized aza-podophyllotoxin derivatives in search of potent anti-tumor agents J. Heterocycl. Chem. 2010, 47, 1275-1282
15. Kumar, A.; Kumar, V.; Alegria, A. E.; Malhotra, S. V. Novel N -hydroxyethyl-4-aza-didehyropodophyllotoxin derivatives, as potential antitumor agents Eur. J. Pharm. Sci. 2011, 44, 21-26
16. Tratrat, C.; Giorgi-Renault, S.; Husson, H. P. A multicomponent reaction for the one-pot synthesis of 4-aza-2,3-didehydropodophyllotoxin and derivatives Org. Lett. 2002, 19, 3187-3189
17. Deng, J. Z.; Newman, D. J.; Hecht, S. M. Use of COMPARE analysis to discover functional analogues of bleomycin J. Nat. Prod. 2000, 63, 1269-1272
18. Shoemaker, R. H. The NCI60 human tumour cell line anticancer drug screen Nature Rev. Cancer 2006, 6, 813-823
19. Liu, J. F.; Wilson, C. J.; Ye, P.; Sprague, K.; Sargent, K.; Si, Y.; Beletsky, G.; Yohannes, D.; Ng, S. C. Privileged structure-based quinazolinone natural product-templated libraries: identification of novel tubulin polymerization inhibitors Bioorg. Med. Chem. Lett. 2006, 16, 686-690
20. Lopus, M.; Oroudjev, E.; Wilson, L.; Wilhelm, S.; Widdison, W.; Chari, R.; Jordan, M. A. Maytansine and cellular metabolites of antibody-maytansinoid conjugates strongly suppress microtubule dynamics by binding to microtubules Mol. Cancer Ther. 2010, 9, 2689-2699
21. De Vincenzo, R.; Ferlini, C.; Distefano, M.; Gaggini, C.; Riva, A.; Bombardelli, E.; Morazzoni, P.; Danieli, B.; Capelli, G.; Mancuso, S.; Scambia, G. Biological evaluation on different human cancer cell lines of novel colchicine analogs Oncol. Res. 1999, 11, 145-152
22. Jordan, M. A.; Kamath, K. How do microtubule-targeted drugs work? An overview Curr. Cancer Drug Targets 2007, 7, 730-742
23. Battaglia, A.; Bernacki, R. J.; Bertucci, C.; Bombardelli, E.; Cimitan, S.; Ferlini, C.; Fontana, G.; Guerrini, A.; Riva, A. Synthesis and biological evaluation of 2-methyl taxoids derived from baccatin III and 14beta-OH-baccatin III 1,14-carbonate J. Med. Chem. 2003, 46, 4822-4825
24. Kortagere, S.; Krasowski, M. D.; Ekins, S. The importance of discerning shape in molecular pharmacology Trends Pharmacol. Sci. 2009, 30, 138-147
25. Kellenberger, E.; Hofmann, A.; Quinn, R. J. Similar interactions of natural products with biosynthetic enzymes and therapeutic targets could explain why nature produces such a large proportion of existing drugs Nat. Prod. Rep. 2011, 28, 1483-1492
26. Weskamp, N.; Huellermeier, E.; Klebe, G. Merging chemical and biological space: structural mapping of enzyme binding pocket space Proteins: Struct., Funct., Bioinf. 2009, 76, 317-330
27. Brylinski, M.; Skolnick, J. A threading-based method (FINDSITE) for ligand-binding site prediction and functional annotation Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 129-134
28. Dinkel, H.; Van Roey, K.; Michael, S.; Davey, N. E.; Weatheritt, R. J.; Born, D.; Speck, T.; Krüger, D.; Grebnev, G.; Kuban, M.; Strumillo, M.; Uyar, B.; Budd, A.; Altenberg, B.; Seiler, M.; Chemes, L. B.; Glavina, J.; Sánchez, I. E.; Diella, F.; Gibson, T. J. The eukaryotic linear motif resource ELM: 10 years and counting Nucleic Acids Res. 2014, 42, D259-D266
29. Leroy, D.; Kajava, A. V.; Frei, C.; Gasser, S. M. Analysis of etoposide binding to subdomains of human DNA topoisomerase II alpha in the absence of DNA Biochemistry 2001, 40, 1624-1634
30. Prakash, B.; Renault, L.; Praefcke, G. J.; Herrmann, C.; Wittinghofer, A. Triphosphate structure of guanylate-binding protein 1 and implications for nucleotide binding and GTPase mechanism EMBO J. 2000, 19, 4555-4564
31. Prakash, B.; Praefcke, G. J.; Renault, L.; Wittinghofer, A.; Herrmann, C. Structure of human guanylate-binding protein 1 representing a unique class of GTP-binding proteins Nature 2000, 403, 567-571
32. Ghosh, A.; Praefcke, G. J.; Renault, L.; Wittinghofer, A.; Herrmann, C. How guanylate-binding proteins achieve assembly-stimulated processive cleavage of GTP to GMP Nature 2006, 440, 101-104
33. Vigil, D.; Cherfils, J.; Rossman, K. L.; Der, C. J. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy? Nature Rev. Cancer 2010, 10, 842-857
34. Vöpel, T.; Syguda, A.; Britzen-Laurent, N.; Kunzelmann, S.; Lüdemann, M. B.; Dovengerds, C.; Stürzl, M.; Herrmann, C. Mechanism of GTPase-activity-induced self-assembly of human guanylate binding protein 1 J. Mol. Biol. 2010, 400, 63-70
35. Ferlini, C.; Cicchillitti, L.; Raspaglio, G.; Bartollino, S.; Cimitan, S.; Bertucci, C.; Mozzetti, S.; Gallo, D.; Persico, M.; Fattorusso, C.; Campiani, G.; Scambia, G. Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77 Cancer Res. 2009, 69, 6906-6914
36. Chiu, J.; March, P. E.; Lee, R.; Tillett, D. Site-Directed, Ligase-Independent Mutagenesis (SLIM): a Single-Tube Methodology Approaching 100% Efficiency in 4 h Nucleic Acids Res. 2004, 32, e174
37. Dauber-Osguthorpe, P.; Roberts, V. A.; Osguthorpe, D. J.; Wolff, J.; Genest, M.; Hagler, A. T. Structure and energetics of ligand binding to proteins: E. coli dihydrofolate reductase-trimethoprim, a drug-receptor system Proteins 1998, 4, 31-47
38. Stewart, J. J. Optimization of parameters for semiempirical methods VI: more modifications to the NDDO approximations and re-optimization of parameters J. Mol. Model. 2013, 19, 1-32
39. Stewart, J. P. MOPAC2012; Computational Chemistry: Colorado Springs, CO, 2012; http://OpenMOPAC.net.
40. Baker, J. An algorithm for the location of transition states J. Comput. Chem. 1986, 7, 385-395
41. Laskowski, R. A.; MacArthur, M. W.; Moss, D. S.; Thornton, J. M. PROCHECK: a program to check the stereochemical quality of protein structures J. Appl. Crystallogr. 1993, 26, 283-291 http://www.ebi.ac.uk/thornton-srv/software/PROCHECK7/
42. Senderowitz, H.; Guarnieri, F.; Still, W. C. A smart Monte Carlo technique for free energy simulations of multiconformational molecules. Direct calculations of the conformational populations of organic molecules J. Am. Chem. Soc. 1995, 117, 8211-8219